Tak­ing aim at Xo­lair, Celldex of­fers a pos­i­tive ear­ly read­out for their ri­val drug — but re­searchers have a lot of work re­main­ing

The re­searchers at Celldex are flag­ging some pos­i­tive da­ta from a small ear­ly stage tri­al for their drug bar­zolvolimab in pa­tients with mod­er­ate to se­vere chron­ic spon­ta­neous ur­ticaria not re­spond­ing to an­ti­his­t­a­mines.

The key fig­ure: The drug trig­gered a 57.1% com­plete re­sponse in the low 1.5 mg/kg dose arm of the tri­al af­ter 12 weeks with the high­er 3.0 mg/kg scor­ing 44% af­ter 8 weeks, which re­flects a sin­gle dose for an on­go­ing treat­ment arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER